Movement Alert｜WUXI XDC Intraday Rise 3.09% in Regular Trading, CXO and life sciences tools stocks rebound

On October 16, WUXI XDC rose 3.09% in regular trading, trading at HK$76.7 per share, with turnover of HK$201 million.

The main catalyst was a rebound in the previously weak CXO and Life Sciences Tools & Services segments, which helped lift sentiment across the group and supported WUXI XDC’s share price recovery.

Recent context shows the stock had been under pressure alongside broader weakness in outsourcing and AI drug discovery names. Earlier disclosures also highlighted supportive fundamentals, including first-half revenue of RMB3.701 billion, up 37.0% year over year, and adjusted net profit of RMB1.027 billion, up 37.4%. In addition, a broker had assigned a Buy rating with a HK$97.9 target price, citing the expected first FDA inspection of its Wuxi facility in the first quarter next year as a longer-term catalyst. On the day, peer moves also pointed to sector-led recovery, with WUXI BIO up 3.31%, WUXI APPTEC up 2.39%, XTALPI up 3.99%, and INSILICO up 5.1%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)